Download PDF
CC BY-NC-ND 4.0 · Revista Urología Colombiana / Colombian Urology Journal 2020; 29(04): 240-244
DOI: 10.1055/s-0040-1701278
Review Article | Artículo de Revisión
General Urology/Urología General

Mecanismos inflamatorios involucrados en la fisiopatología de la hiperplasia prostática benigna

Inflammatory Mechanisms Involved in the Pathophysiology of Benign Prostatic Hyperplasia
Ximena Guzman Robledo
1   Universidad del Valle, Cali, Colombia
,
Herney Andrés García-Perdomo 
2   Escuela de Medicina, Grupo de Investigación UROGIV, Universidad del Valle, Cali, Colombia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Resumen

La obstrucción del tracto de salida ha sido asociada con la hiperplasia prostática benigna (HPB), dado el crecimiento progresivo del adenoma, lo cual lleva a un incremento en la resistencia al flujo urinario, junto con un efecto deletéreo en la función renal. Se han descrito múltiples teorías asociadas con el desarrollo de la hiperplasia. Entre las cuales se encuentran: La edad, el incremento en la actividad simpática, alteraciones hormonales, el síndrome metabólico y la inflamación crónica. En los últimos años, el rol de la inflamación prostática local en el entendimiento de la patogénesis y progresión de la HPB ha cobrado relevancia. Esa hipótesis plantea que infiltrados inflamatorios conllevan a una lesión tisular, generando así un proceso crónico de cicatrización que condiciona el incremento en el tamaño prostático. El presente artículo se enfoca en describir los mecanismos inflamatorios involucrados en la fisiopatología de la hiperplasia prostática benigna.

Abstract

Urinary tract obstruction has been associated with benign prostatic hyperplasia (BPH), given the progressive adenoma growth. This process leads to an increase in urinary flow resistance, associated with a deleterious effect of renal function. Age, increased sympathetic activity, hormonal alterations, metabolic syndrome and chronic inflammation are among the multiple theories associated with the development of hyperplasia. In recent years, the role of local prostatic inflammation in understanding the pathogenesis and progression of BPH has become relevant. This hypothesis suggests that inflammatory infiltrates lead to a tissue injury, thus generating a chronic healing process that conditions the prostatic increase. The present article focuses on describing the inflammatory mechanisms involved on BPH pathophysiology.

Palabras Clave

hiperplasia prostática benigna - obstrucción del tracto de salida - inflamación crónica

Keywords

benign prostatic hyperplasia - obstruction of the outflow tract - chronic inflammation


Publication History

Received: 19 April 2019

Accepted: 02 December 2019

Article published online:
11 March 2020

© 2020. Sociedad Colombiana de Urología. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • Referencias

  • 1 Burgos J. Inflammation and Prostatic Diseases: From Bench to Bedside. Eur Urol Suppl 2015; 14 (09) e1453-e1454
    CrossrefPubMedGoogle Scholar
  • 2 Schalken JA. Inflammation in the Pathophysiology of Benign Prostatic Hypertrophy. Eur Urol Suppl 2015; 14 (09) e1455-e1458
    CrossrefPubMedGoogle Scholar
  • 3 Bushman WA, Jerde TJ. Role of Prostate Inflammation and Fibrosis in Benign Prostate Hyperplasia and Lower Urinary Tract Symptoms. Am J Physiol Ren Physiol 2016
    Google Scholar
  • 4 Abrams P, Cardozo L, Fall M. et al; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61 (01) 37-49
    CrossrefPubMedGoogle Scholar
  • 5 Gandaglia G, Briganti A, Gontero P. et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013; 112 (04) 432-441
    CrossrefPubMedGoogle Scholar
  • 6 Chughtai B, Forde JC, Thomas DDM. et al. Benign prostatic hyperplasia. Nat Rev Dis Primers 2016; 2: 16031
    CrossrefPubMedGoogle Scholar
  • 7 Ngai H-Y, Yuen KS, Ng C-M, Cheng C-H, Chu SP. Metabolic syndrome and benign prostatic hyperplasia: An update. Asian J Urol 2017; 4 (03) 164-173
    CrossrefPubMedGoogle Scholar
  • 8 De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61 (03) 560-570
    CrossrefPubMedGoogle Scholar
  • 9 Yang T-K, Hsieh J-T, Chen S-C, Chang H-C, Yang H-J, Huang K-H. Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup. Urology 2012; 80 (05) 1093-1097
    CrossrefPubMedGoogle Scholar
  • 10 Liu L, Li Q, Han P. et al. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology 2009; 74 (02) 340-344
    CrossrefPubMedGoogle Scholar
  • 11 Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory Process in Type 2 Diabetes: The Role of Cytokines. Ann N Y Acad Sci 2006; 1084 (01) 89-117
    CrossrefPubMedGoogle Scholar
  • 12 Asiedu B, Anang Y, Nyarko A. et al. The role of sex steroid hormones in benign prostatic hyperplasia. Aging Male 2017; 20 (01) 17-22
    CrossrefPubMedGoogle Scholar
  • 13 Wu Y, Pan H, Wang W-M. et al. A possible relationship between serum sex hormones and benign prostatic hyperplasia/lower urinary tract symptoms in men who underwent transurethral prostate resection. Asian J Androl 2017; 19 (02) 230-233
    CrossrefPubMedGoogle Scholar
  • 14 Higashi Y. Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3′,5′-monophosphate pathway. Int J Urol 2017; 24 (06) 412-424
    CrossrefPubMedGoogle Scholar
  • 15 De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol 2016; 13 (10) 613-626
    CrossrefPubMedGoogle Scholar
  • 16 Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention. J Urol 2016; 196 (05) 1493-1498
    CrossrefPubMedGoogle Scholar